CytoDyn Inc. (CYDY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 05-31. Amounts in USD.

Revenue Quarterly

0 80K 160K 240K Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 41K Q2 '22: 225K Q3 '22: 0 Q4 '22: 0 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22

Gross Profit Quarterly

0 60K 120K 180K Q1 '22: 40K Q2 '22: 173K Q3 '22: 0 Q4 '22: 0 Q1 '22 Q2 '22 Q3 '22 Q4 '22

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q4 '21: -23.6M Q1 '22: -21.6M Q2 '22: -25.3M Q3 '22: -19.4M Q4 '22: -79M Q1 '23: -9.7M Q2 '23: -23.2M Q3 '23: -3.9M Q4 '23: -3.8M Q1 '24: -4.6M Q2 '24: -3.4M Q3 '24: -3.4M Q4 '24: -6.6M Q1 '25: 22.4M Q2 '25: -3.7M Q3 '25: -4M Q4 '25: -5.1M Q1 '26: -4.9M Q2 '26: -21.7M Q3 '26: -6.3M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q4 '21: -70.1M Q1 '22: -45.3M Q2 '22: -40.1M Q3 '22: -41.3M Q4 '22: -84.1M Q1 '23: -21M Q2 '23: -26.5M Q3 '23: -13.7M Q4 '23: -18.6M Q1 '24: -11.6M Q2 '24: -9.6M Q3 '24: -11.9M Q4 '24: -16.8M Q1 '25: 19.2M Q2 '25: -4.8M Q3 '25: -4.8M Q4 '25: -6M Q1 '26: -5.5M Q2 '26: -22.6M Q3 '26: -4.7M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Cost of Revenue Quarterly

0 20K 40K 60K Q1 '22: 1K Q2 '22: 52K Q3 '22: 0 Q4 '22: 0 Q1 '22 Q2 '22 Q3 '22 Q4 '22

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q4 '21: -32.8M Q1 '22: -31.7M Q2 '22: -28.9M Q3 '22: -11M Q4 '22: -6M Q1 '23: -11.1M Q2 '23: -4.4M Q3 '23: -6.2M Q4 '23: -3.4M Q1 '24: -4.5M Q2 '24: -2.5M Q3 '24: -2.3M Q4 '24: -1.6M Q1 '25: 5.4M Q2 '25: -3.6M Q3 '25: -5M Q4 '25: -5.7M Q1 '26: -2.5M Q2 '26: -4.3M Q3 '26: -5.5M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '17: -6.3M Q2 '17: -4.5M Q3 '17: -8.8M Q4 '17: -7.2M Q4 '18: -7M Q1 '19: -9M Q2 '19: -17.2M Q3 '19: -14.8M Q4 '19: -9.5M Q1 '20: -15.2M Q2 '20: -6.8M Q3 '20: -17.5M Q4 '20: -29.3M Q1 '21: -41M Q2 '21: -20.2M Q3 '21: -23.7M Q4 '21: -32.8M Q1 '22: -31.7M Q2 '22: -28.9M Q3 '22: -11.1M Q2 '17 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q4 '21 Q3 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 500M 1B 1.5B Q2 '21: 577.9M Q3 '21: 577.9K Q1 '22: 632.6M Q2 '22: 662.6M Q3 '22: 695.6M Q1 '23: 787.9M Q2 '23: 813.4M Q3 '23: 832.2M Q1 '24: 923.6M Q2 '24: 959M Q3 '24: 982.2M Q1 '25: 1.2B Q2 '25: 1.2B Q3 '25: 1.2B Q1 '26: 1.3B Q2 '26: 1.3B Q3 '26: 1.3B Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.45 -0.30 -0.15 0.00 0.15 0.30 0.45 Q4 '18: -0.22 Q1 '19: -0.26 Q2 '19: -0.29 Q3 '22: -0.31 Q4 '22: -0.31 Q1 '23: -0.27 Q2 '23: -0.24 Q3 '23: -0.20 Q4 '23: -0.10 Q1 '24: -0.08 Q2 '24: -0.06 Q3 '24: -0.05 Q4 '24: -0.04 Q1 '25: -0.01 Q2 '25: -0.00 Q3 '25: 0.01 Q4 '25: 0.00 Q1 '26: -0.02 Q2 '26: -0.04 Q3 '26: -0.04 Q1 '19 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.